Have a feature idea you'd love to see implemented?
Let us know!
ARDX Ardelyx Inc
Price (delayed)
$4.905
Market cap
$1.16B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.31
Enterprise value
$1.22B
Ardelyx is focused on discovering, developing, and commercializing innovative first-in-class medicines to enhance the lives of patients with kidney and cardiorenal diseases. Ardelyx is advancing tenapanor, a novel product candidate
Highlights
The company's revenue has surged by 88% YoY and by 20% QoQ
The company's gross profit has surged by 81% YoY and by 19% QoQ
Ardelyx's equity has decreased by 17% YoY but it has increased by 8% QoQ
The net income has plunged by 173% YoY and by 11% from the previous quarter
The company's quick ratio fell by 28% YoY and by 3.1% QoQ
Key stats
What are the main financial stats of ARDX
Market
Valuations
Earnings
Shares outstanding
236.85M
Market cap
$1.16B
Enterprise value
$1.22B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.29
Price to sales (P/S)
4.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.84
Revenue
$251.85M
Gross profit
$214.48M
Net income
-$72.58M
EBIT
-$61.24M
EBITDA
-$55.42M
Free cash flow
-$63.8M
Per share
Balance sheet
Liquidity
EPS
-$0.31
EPS diluted
-$0.31
Free cash flow per share
-$0.27
Book value per share
$0.67
Revenue per share
$1.07
TBVPS
$1.56
Total assets
$367.86M
Total liabilities
$209.57M
Debt
$104.49M
Equity
$158.3M
Working capital
$213.6M
Debt to equity
0.66
Current ratio
4.03
Quick ratio
3.46
Net debt/EBITDA
-1.03
Margins
Efficiency
Dividend
EBITDA margin
-22%
Gross margin
85.2%
Net margin
-28.8%
Operating margin
-25.4%
Return on assets
-21.5%
Return on equity
-46.6%
Return on invested capital
-18.4%
Return on capital employed
-20.6%
Return on sales
-24.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ARDX stock price
How has the Ardelyx stock price performed over time
Intraday
-0.1%
1 week
-8.32%
1 month
1.76%
1 year
-44.39%
YTD
-3.25%
QTD
-3.25%
Financial performance
How have Ardelyx's revenue and profit performed over time
Revenue
$251.85M
Gross profit
$214.48M
Operating income
-$64.06M
Net income
-$72.58M
Gross margin
85.2%
Net margin
-28.8%
The company's operating income has shrunk by 177% YoY and by 9% QoQ
The net income has plunged by 173% YoY and by 11% from the previous quarter
The company's revenue has surged by 88% YoY and by 20% QoQ
The company's gross profit has surged by 81% YoY and by 19% QoQ
Growth
What is Ardelyx's growth rate over time
Valuation
What is Ardelyx stock price valuation
P/E
N/A
P/B
7.29
P/S
4.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.84
The EPS has declined by 11% since the previous quarter
ARDX's P/B is 35% above its 5-year quarterly average of 5.4 but 30% below its last 4 quarters average of 10.5
Ardelyx's equity has decreased by 17% YoY but it has increased by 8% QoQ
The company's revenue has surged by 88% YoY and by 20% QoQ
The price to sales (P/S) is 85% lower than the 5-year quarterly average of 30.1 and 49% lower than the last 4 quarters average of 9.1
Efficiency
How efficient is Ardelyx business performance
Ardelyx's ROE has plunged by 135% YoY and by 17% from the previous quarter
Ardelyx's ROA has plunged by 84% YoY and by 4.9% from the previous quarter
The return on sales has declined by 47% year-on-year but it has increased by 9% since the previous quarter
The company's return on invested capital fell by 17% YoY
Dividends
What is ARDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ARDX.
Financial health
How did Ardelyx financials performed over time
ARDX's total assets is 76% greater than its total liabilities
ARDX's total liabilities has surged by 113% year-on-year and by 7% since the previous quarter
The company's quick ratio fell by 28% YoY and by 3.1% QoQ
Ardelyx's debt is 34% lower than its equity
Ardelyx's equity has decreased by 17% YoY but it has increased by 8% QoQ
Ardelyx's debt to equity has decreased by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.